UNSPSC 51283103: Cilofungin

This classification denotes an antifungal agent with the molecular formula C49H71N7O17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ZJC54A39X, chemically known as 1-((4r,5r)-4,5-dihydroxy-n(sup 2)-(p-(octyloxy)benzoyl)-l-ornithine)echinocandin b but generally known as cilofungin, which bears US NIH Compound Identifier 71762. European Medicines Agency schedules Cilofungin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06271MIG.

UNSPSC 51283103 Cilofungin is a Commodity code nominally addressing a specific antifungal pharmaceutical agent, but state and local procurement activity under this code does not reflect targeted cilofungin purchasing. Instead, the recent opportunities tagged to this code show state and local governments soliciting broadly across pharmaceutical and medical supply categories — generic multi-source drugs, over-the-counter products, naloxone, first aid supplies, and direct-to-manufacturer prescription fulfillment programs. The issuing bodies span county health departments, state pharmacy benefit administrators, municipal fire departments, and regional cooperative purchasing alliances. Work actually being solicited ranges from high-volume consumable medical supplies for emergency response (respiratory equipment, cardiac monitoring electrodes, bandaging materials) to strategic pharmaceutical sourcing through direct-to-manufacturer contracting models and cooperative purchasing vehicles.

Recent activity appears concentrated in Florida, Texas, Minnesota, and Oregon, with the strongest volume signals from state-level cooperative arrangements and county health procurement. Representative current opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, though the posting date of June 30, 2026 suggests a data inconsistency in the source), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract amount of $700,000.00 and a sheltered small local business enterprise set-aside (response deadline March 13, 2026), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products to multiple state and local jurisdictions (due March 26, 2026), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026). The mismatch between the cilofungin code's narrow pharmaceutical scope and the broad medical-supply purchasing actually tagged to it suggests this code may see limited relevance for vendors pursuing targeted antifungal contracts through state and local channels.